Clinical Trial: A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX(R) in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895512) titled 'A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX(R) in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma' on March 10.

Brief Summary: This is a randomized, double-blind, parallel-controlled, multicenter, phase III study to compare the efficacy and safety of HLX15-IV in combination with Rd (HLX15-IV-Rd) versus DARZALEX(R) in combination with Rd (D-Rd) in patients with NDMM who are ineligible for autologous stem cell transplantation (ASCT).

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Newly Diagnosed Multiple Myelo...